Abstract
In patients with chronic heart failure increased sympathetic activity is related to unfavourable prognosis. Since myocardial iodine-123 metaiodobenzylguanidine ([123I]MIBG) uptake is related to myocardial noradrenaline content, i.e. cardiac sympathetic activity, measurement of myocardial [123I]MIBG uptake may be of clinical use in determining prognosis or the effect of pharmacological intervention in these patients. The aim of the present study was to evaluate a new method to quantitate myocardial [123I]MIBG uptake with respect to reproducibility and accuracy. Eighteen [123I]MIBG planar and single-photon emission tomography (SPET) studies of patients with chronic heart failure were evaluated. Myocardial uptake was calculated from the myocardial (MYO) to left ventricular cavity (C) count density ratio and the123I activity in a blood sample. This was performed employing planar LAO images, a single-slice SPET method using the midventricular myocardial short-axis slice, and finally a multi-slice SPET method analysing semi-automatically drawn volumes of interest (VOIs). The accuracy of the multi-slice SPET method was verified using a cardiac phantom. The planar method was found to be reproducible [intra- and interobserver coefficients of variation (IACV and IRCV) were 0.025 and 0.012 respectively] but the mean MYO/C count density ratio was only 1.31±0.16 as a consequence of overprojection. For the single-slice SPET method IACV was 0.2 and IRCV was 0.13, representing poor reproducibility. For the multi-slice SPET method IACV was 0.051, IRCV was 0.047 and the mean MYO/C count density ratio was 5.4±2.42. Accuracy was 81% at a true MYO/C count density ratio of 6 in the phantom. It is concluded that the multi-slice SPET method using the left ventricular cavity VOI and a blood sample as a reference is a reproducible and accurate method for assessing myocardial [123I]MIBG uptake.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Tobes MC, Jaques S Jr, Wieland DM, Sisson JC. Effect of uptake-one inhibitors on the uptake of norepinephrine and metaiodobenzylguanidine.J Nucl Med 1985; 26: 897–907.
Mangner TJ, Tobes MC, Wieland DW Sisson JC, Shapiro B. Metabolism of iodine-131 metaiodobenzylguanidine in patients with metastatic pheochromocytoma.J Nucl Med 1986; 27: 37–44.
Sisson JC, Wieland DM, Sherman P, Mangner TJ, Tobes MC, Jacques S Jr. Metaiodobenzylguanidine as an index of the adrenergic nervous system integrity and function. J Nucl Med 1987; 28: 1620–1624.
Simmons WW, Freeman MR, Grima EA, Hsia TW, Armstrong PW. Abnormalities of cardiac sympathetic function in pacing-induced heart failure as assessed by [123I]-metaiodo-benzylguanidine scintigraphy.Circulation 1994; 89: 2843–2851.
Henderson EB, Kahn JK, Corbett JR et al. Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy.Circulation 1988; 78: 1192–1199.
Dae MW, De Marco T, Botvinick EH, O'Connell JW, Hattner RS, Huberty JP, Yuen Green MS. Scintigraphic assessment of MIBG uptake in globally denervated human and canine hearts — implications for clinical studies.J Nucl Med 1992; 33: 1444–1450.
Stanton MS, Tuli MM, Radtke NL, Heger JJ, Miles WM, Mock BH, Burt RW Wellman HN, Zipes DP. Regional sympathetic denervation after maocardial infarction in humans detected noninvasively using I-123-metaiodobenzylguanidine.J Am Coll Cardiol 1989; 14: 1519–1526.
Sisson JC, Shapiro B, Meyers L, Mallette S, Mangner TJ, Wieland DM, Sherman P, Beierwaltes WH. Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man.J Nucl Med 187; 28: 1625–1636.
Mantysaari M, Kuikka J, Mustonen J, Tahvanainen K, Vanninen E, Lansimies E, Uusitupa M. Noninvasive detection of cardiac sympathetic nervous dysfunction in diabetic patients using [123I]-metaiodobenzylguanidine.Diabetes 1992; 41: 1069–1075.
Merlet P, Valette H, Dubois Rande JL et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure.J Nucl Med 1992; 33: 471–477.
Shakespeare CF, Page CJ, O'Doherty MJ, Nunan TO, Cooper IC, Katritsis D, Coltart DJ. Regional sympathetic innervation of the heart by means of metaiodobenzylguanidine imaging in silent ischemia.Am Heart J 1993; 125: 1614–1622.
Mitrani RD, Klein LS, Miles WM, Hackett FK, Burt RW Wellman HN, Zipes DP. Regional cardiac sympathetic denervation in patients with ventricular tachycardia in the absence of coronary artery disease.J Am Coll Cardiol 1993; 22: 1344–1353.
Schofer J, Spielmann R, Schuchert A, Weber K, Schluter M. Iodine-123 meta-iodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy.JAm Coll Cardiol 1988; 12: 1252–1258.
Doremalen PAPM, Janssen AGM. A rapid and high-yield aqueous phase preparation procedure for123I-labelled metaiodobenzylguanidine.J Radioanal Nucl Chem 1985; 96: 97–104.
Britton KE, Bardoux C.Quality assurance on nuclear medicine software, COST project B2. 1991
Gill JS, Hunter GJ, Gane G, Camm AJ. Heterogeneity of the human myocardial sympathetic innervation: in vivo demonstration by iodine 123-labeled meta-iodobenzylguanidine scintigraphy.Am Heart J 1993; 126: 390–398.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Somsen, G.A., Borm, J.J.J., de Milliano, P.A.R. et al. Quantitation of myocardial iodine-123 MIBG uptake in SPET studies: a new approach using the left ventricular cavity and a blood sample as a reference. Eur J Nucl Med 22, 1149–1154 (1995). https://doi.org/10.1007/BF00800597
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00800597